Elixir Medical has earned the CE mark to market its DESolve Novolimus-eluting coronary stent in Europe. The bioresorbable stent, which is used to treat patients with coronary artery disease, degrades in the body in about a year, restoring the treated vessel to its normal de novo state. The company aims for a limited global release of the device later in the year.

Related Summaries